Alcon Inc. Ordinary Shares ALC

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

• The Motley Fool 13 ago

  Bill Ackman’s Pershing Square Just Bought Netflix and 5 Other Stocks. Here’s What Investors Need to Know.

  Bill Ackman's Pershing Square deployed 85% of its $5 billion capital raise by purchasing Netflix, Visa, Mastercard, S&P Global, Intercontinental Exchange, and Alcon. The fund targeted stocks that have sold off due to AI disruption concerns, believing these companies have competitive advantages that will allow them to thrive despite AI-related headwinds.

  

• GlobeNewswire Inc. 13 jul

  Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 Others

  The global ophthalmology devices market is projected to grow from $56.61 billion in 2025 to $99.22 billion by 2030, with a CAGR of 11.9%. Key growth drivers include rising demand for minimally invasive surgeries, an aging population, increased eye disorders, and innovation in precision surgical tools. Leading companies include EssilorLuxottica, Alcon, Bausch + Lomb, and HOYA Corporation, with North America currently leading the market while Asia-Pacific shows rapid growth potential.

  

• The Motley Fool 8 jul

  Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?

  Abbott Laboratories and Glaukos represent two contrasting healthcare investment strategies: Abbott offers stability through diversification, strong profitability, and recent acquisitions like Exact Sciences, while Glaukos provides high-growth potential in specialized ophthalmic treatments with innovative products like iDose and Epioxa. Abbott trades at a lower valuation multiple but faces integration challenges and legal risks, while Glaukos shows rapid 32% revenue growth but remains unprofitable and dependent on a single manufacturing location.